Anders Ãsberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2695407/publications.pdf

Version: 2024-02-01

237	8,332	53660	56606
papers	citations	45 h-index	83 g-index

241	241	241	8138
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation, 2010, 89, 779-795.	0.5	898
2	Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation. Transplantation, 2013, 96, 333-360.	0.5	651
3	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	1.0	374
4	Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients. American Journal of Transplantation, 2007, 7, 2106-2113.	2.6	366
5	The European Renal Associationâ€‰â€“â€‰European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary. CKJ: Clinical Kidney Journal, 2019, 12, 702-720.	1.4	178
6	The European Renal Association â€“ European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. CKJ: Clinical Kidney Journal, 2018, 11, 108-122.	1.4	169
7	Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients. American Journal of Transplantation, 2009, 9, 1205-1213.	2.6	161
8	Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus. American Journal of Transplantation, 2005, 5, 2236-2243.	2.6	132
9	Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin. Drug Metabolism and Disposition, 2010, 38, 1499-1504.	1.7	127
10	Interactions Between Cyclosporin and Lipid-Lowering Drugs. Drugs, 2003, 63, 367-378.	4.9	126
11	Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients. American Journal of Transplantation, 2001, 1, 382-386.	2.6	124
12	Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes Care, 2019, 42, 1067-1074.	4.3	121
13	Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clinical Pharmacology and Therapeutics, 2006, 79, 532-539.	2.3	119
14	Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. European Journal of Pharmaceutical Sciences, 2008, 33, 317-325.	1.9	110
15	The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. European Journal of Clinical Pharmacology, 2014, 70, 685-693.	0.8	107
16	Incidence and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infections in 1244 Kidney Transplant Recipients. Transplantation, 2011, 92, 217-223.	0.5	97
17	Impact of Genetic Polymorphisms in Cytomegalovirus Glycoprotein B on Outcomes in Solidâ€Organ Transplant Recipients with Cytomegalovirus Disease. Clinical Infectious Diseases, 2009, 49, 1160-1166.	2.9	96
18	Importance of hematocrit for a tacrolimus target concentration strategy. European Journal of Clinical Pharmacology, 2014, 70, 65-77.	0.8	92

#	Article	IF	Citations
19	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	1.0	89
20	The Clinical Utility of Whole Blood Versus Plasma Cytomegalovirus Viral Load Assays for Monitoring Therapeutic Response. Transplantation, 2011, 91, 231-236.	0.5	87
21	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antiviral Therapy, 2009, 14, 697-704.	0.6	86
22	Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects. Clinical Pharmacology and Therapeutics, 2013, 93, 275-282.	2.3	82
23	Virologic Suppression Measured by a Cytomegalovirus (CMV) DNA Test Calibrated to the World Health Organization International Standard Is Predictive of CMV Disease Resolution in Transplant Recipients. Clinical Infectious Diseases, 2013, 56, 1546-1553.	2.9	79
24	Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrology Dialysis Transplantation, 2014, 29, 926-933.	0.4	78
25	Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipientsâ€"A Prospective, Randomized Study. Transplantation, 2015, 99, 2158-2166.	0.5	77
26	Effects of the Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease in Organ Transplant Recipients. American Journal of Transplantation, 2010, 10, 1881-1888.	2.6	76
27	Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro. Drug Metabolism and Disposition, 2012, 40, 655-661.	1.7	75
28	Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All-Cause Mortality in Kidney Transplant Recipients. American Journal of Transplantation, 2016, 16, 204-212.	2.6	74
29	Significantly Altered Systemic Exposure to Atorvastatin Acid Following Gastric Bypass Surgery in Morbidly Obese Patients. Clinical Pharmacology and Therapeutics, 2009, 86, 311-318.	2.3	73
30	An Assessment of Herpesvirus Co-infections in Patients with CMV Disease: Correlation with Clinical and Virologic Outcomes. American Journal of Transplantation, 2009, 9, 374-381.	2.6	70
31	Improved prediction of tacrolimus concentrations early after kidney transplantation using theoryâ€based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 2014, 78, 509-523.	1.1	67
32	The ERA-EDTA Registry Annual Report 2018: a summary. CKJ: Clinical Kidney Journal, 2021, 14, 107-123.	1.4	67
33	The ERA-EDTA Registry Annual Report 2017: a summary. CKJ: Clinical Kidney Journal, 2020, 13, 693-709.	1.4	65
34	The European Renal Association â€" European Dialysis and Transplant Association Registry Annual Report 2014: a summary. CKJ: Clinical Kidney Journal, 2017, 10, 154-169.	1.4	64
35	Declining Intracellular T-Lymphocyte Concentration of Cyclosporine A Precedes Acute Rejection in Kidney Transplant Recipients. Transplantation, 2008, 85, 179-184.	0.5	60
36	Inclusion of <scp>CYP</scp> 3 <scp>A</scp> 5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transplant International, 2013, 26, 1198-1207.	0.8	60

#	Article	IF	Citations
37	Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrology Dialysis Transplantation, 2005, 20, 413-418.	0.4	57
38	Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clinical Pharmacology and Therapeutics, 2004, 76, 388-391.	2.3	56
39	Exposure to Mycophenolate and Fatherhood. Transplantation, 2017, 101, e214-e217.	0.5	56
40	The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review. Obesity Reviews, 2019, 20, 1299-1311.	3.1	53
41	Atorvastatin improves endothelial function in renalâ€transplant recipients. Nephrology Dialysis Transplantation, 2001, 16, 1920-1924.	0.4	52
42	Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrology Dialysis Transplantation, 2003, 18, 1899-1908.	0.4	52
43	Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. European Journal of Clinical Pharmacology, 2002, 58, 515-520.	0.8	51
44	Reduced Elimination of Cyclosporine A in Elderly (>65 Years) Kidney Transplant Recipients. Transplantation, 2008, 86, 1379-1383.	0.5	49
45	A 1-Year Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ibandronate on Bone Loss Following Renal Transplantation. American Journal of Transplantation, 2012, 12, 3316-3325.	2.6	49
46	GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. Diabetes Care, 2016, 39, 617-624.	4.3	46
47	Nonspecific Microvascular Vasodilation during Iontophoresis Is Attenuated by Application of Hyperosmolar Saline. Microvascular Research, 1999, 58, 41-48.	1.1	44
48	New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatric Transplantation, 2014, 18, 103-111.	0.5	44
49	Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria. Transplant International, 2016, 29, 568-578.	0.8	43
50	Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients. Therapeutic Drug Monitoring, 2019, 41, 607-614.	1.0	43
51	Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrology Dialysis Transplantation, 2007, 23, 1048-1053.	0.4	42
52	Aortic Stiffness in a Mortality Risk Calculator for Kidney Transplant Recipients. Transplantation, 2015, 99, 1730-1737.	0.5	42
53	Use of Generic Tacrolimus in Elderly Renal Transplant Recipients. Transplantation, 2015, 99, 528-532.	0.5	42
54	Calcineurin Inhibitor Avoidance with Daclizumab, Mycophenolate Mofetil, and Prednisolone in DR-Matched de Novo Kidney Transplant Recipients. Transplantation, 2006, 82, 62-68.	0.5	41

#	Article	IF	Citations
55	Analysis and clinical correlation of genetic variation in cytomegalovirus. Transplant Infectious Disease, 2012, 14, 132-140.	0.7	41
56	High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. Transplantation, 2017, 101, e273-e279.	0.5	40
57	Global variability analysis of mRNA and protein concentrations across and within human tissues. NAR Genomics and Bioinformatics, 2020, 2, lqz010.	1.5	40
58	Significant Increase in Systemic Exposure of Atorvastatin After Biliopancreatic Diversion With Duodenal Switch. Clinical Pharmacology and Therapeutics, 2010, 87, 699-705.	2.3	39
59	Desacetyl-Diltiazem Displays Severalfold Higher Affinity to CYP2D6 Compared with CYP3A4. Drug Metabolism and Disposition, 2002, 30, 1-3.	1.7	38
60	New-Onset Posttransplantation Diabetes Mellitus: Insulin Resistance or Insulinopenia? Impact of Immunosuppressive Drugs, Cytomegalovirus and Hepatitis C Virus Infection. Current Diabetes Reviews, 2005, 1, 1-10.	0.6	38
61	Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies. Transplantation, 2017, 101, 1410-1415.	0.5	38
62	Pulmonary Hemodynamics and Plasma Endothelin-1 during Hypoxemia and Reoxygenation with Room Air or 100% Oxygen in a Piglet Model. Pediatric Research, 1998, 44, 843-849.	1.1	37
63	Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients. European Journal of Clinical Pharmacology, 1999, 55, 383-387.	0.8	35
64	Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 345-352.	1.2	35
65	OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. Biochemical Pharmacology, 2011, 82, 1219-1226.	2.0	35
66	CYP2D6 is involved in O-demethylation of diltiazem. European Journal of Clinical Pharmacology, 2000, 56, 575-579.	0.8	34
67	The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. Nephrology Dialysis Transplantation, 2007, 22, 1743-1749.	0.4	34
68	Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout (Oncorhynchus mykiss) hepatocytes. Toxicology in Vitro, 2010, 24, 1610-1618.	1.1	34
69	Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 2094-2101.	1.3	34
70	Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose. Pharmacological Research, 2018, 130, 316-321.	3.1	34
71	The Concentration of Cyclosporine Metabolites Is Significantly Lower in Kidney Transplant Recipients With Diabetes Mellitus. Therapeutic Drug Monitoring, 2012, 34, 38-45.	1.0	31
72	Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes. Journal of Pharmaceutical Sciences, 2021, 110, 432-437.	1.6	31

#	Article	IF	Citations
73	Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation - a single-centre open prospective trial. Transplant International, 2019, 32, 614-625.	0.8	30
74	Immunosuppression and Reproductive Health After Kidney Transplantation. Transplantation, 2019, 103, e325-e333.	0.5	30
75	Limitations of Hemoglobin A1c for the Diagnosis of Posttransplant Diabetes Mellitus. Transplantation, 2015, 99, 629-635.	0.5	29
76	Associations Between Posttransplantation Diabetes Mellitus and Renal Graft Survival. Transplantation, 2017, 101, 1282-1289.	0.5	29
77	Hcmv-miR-UL22A-5p: A Biomarker in Transplantation With Broad Impact on Host Gene Expression and Potential Immunological Implications. American Journal of Transplantation, 2015, 15, 1893-1902.	2.6	28
78	A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity. Drug Metabolism and Disposition, 2020, 48, 8-17.	1.7	27
79	Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation. Transplant International, 2015, 28, 1162-1171.	0.8	26
80	Outcomes in Pancreas Transplantation With Exocrine Drainage Through a Duodenoduodenostomy Versus Duodenojejunostomy. American Journal of Transplantation, 2018, 18, 154-162.	2.6	26
81	Better microvascular function on longâ€term treatment with lisinopril than with nifedipine in renal transplant recipients. Nephrology Dialysis Transplantation, 2001, 16, 1465-1470.	0.4	24
82	Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial. Clinical Infectious Diseases, 2016, 62, 1154-1160.	2.9	24
83	Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response. American Journal of Transplantation, 2022, 22, 2704-2706.	2.6	24
84	Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients. Transplantation Research, 2012, 1, 9.	1.5	23
85	First Scandinavian Protocol for Controlled Donation After Circulatory Death Using Normothermic Regional Perfusion. Transplantation Direct, 2018, 4, e366.	0.8	23
86	Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. Basic Research in Cardiology, 2002, 97, 239-247.	2.5	21
87	Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone Metabolite. Clinical Pharmacokinetics, 2010, 49, 693-702.	1.6	20
88	Evaluation of Organic Anion-Transporting Polypeptide 1B1 and CYP3A4 Activities in Primary Human Hepatocytes and HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor System. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 145-156.	1.3	20
89	Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling. Therapeutic Drug Monitoring, 2020, 42, 407-414.	1.0	20
90	Atorvastatin Metabolite Measurements as a Diagnostic Tool for Statin-Induced Myopathy. Molecular Diagnosis and Therapy, 2011, 15, 221-227.	1.6	19

#	Article	IF	Citations
91	A drug safety evaluation of everolimus in kidney transplantation. Expert Opinion on Drug Safety, 2012, 11, 1013-1022.	1.0	19
92	UGT1A1*28 is Associated with Decreased Systemic Exposure of Atorvastatin Lactone. Molecular Diagnosis and Therapy, 2013, 17, 233-237.	1.6	19
93	The CYP3A biomarker 4Î²â€hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. British Journal of Clinical Pharmacology, 2017, 83, 1457-1465.	1.1	19
94	Inflammatory and related biomarkers are associated with post-transplant diabetes mellitus in kidney recipients: a retrospective study. Transplant International, 2018, 31, 510-519.	0.8	19
95	A Population Pharmacokinetic Model of Ciclosporin Applicable for Assisting Dose Management of Kidney Transplant Recipients. Clinical Pharmacokinetics, 2009, 48, 615-623.	1.6	18
96	Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1039-1044.	1.4	17
97	Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. Clinical Transplantation, 2009, 23, 511-518.	0.8	17
98	Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population. Transplantation Direct, 2017, 3, e332.	0.8	17
99	Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). BMJ Open, 2018, 8, e021878.	0.8	17
100	Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Clinical Transplantation, 1998, 12, 553-6.	0.8	17
101	A simple and sensitive high-performance liquid chromatography assay of diltiazem and main metabolites in renal transplanted patients. Clinica Chimica Acta, 1999, 283, 63-75.	0.5	16
102	Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients. Transplantation, 2012, 94, 1060-1065.	0.5	16
103	More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients. Transplantation, 2014, 97, 1266-1271.	0.5	16
104	Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial. American Journal of Transplantation, 2019, 19, 790-800.	2.6	16
105	High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study. Transplant International, 2019, 32, 257-269.	0.8	16
106	Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patientsâ€"A Cross-Validation Study. Therapeutic Drug Monitoring, 2021, 43, 371-375.	1.0	16
107	Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up!. Transplantation, 2021, 105, e80-e81.	0.5	16
108	Drug Disposition Protein Quantification in Matched Human Jejunum and Liver From Donors With Obesity. Clinical Pharmacology and Therapeutics, 2022, 111, 1142-1154.	2.3	16

#	Article	IF	Citations
109	Each Administration of Cyclosporin A Enhances Skin Microvascular Reactivity in Renal Transplant Recipients. Microvascular Research, 2000, 60, 81-90.	1.1	15
110	Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation, 2003, 17, 385-390.	0.8	15
111	Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Review of Cardiovascular Therapy, 2004, 2, 641-652.	0.6	15
112	Vitamin D as a risk factor for patient survival after kidney transplantation: A prospective observational cohort study. Clinical Transplantation, 2019, 33, e13517.	0.8	15
113	Pharmacokinetics of a novel, approved, 1.4â€‰mg intranasal naloxone formulation for reversal of opioid overdoseâ€”a randomized controlled trial. Addiction, 2019, 114, 859-867.	1.7	15
114	Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation. BMC Nephrology, 2019, 20, 12.	0.8	15
115	Proteomicsâ€Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight. Clinical Pharmacology and Therapeutics, 2021, 109, 762-771.	2.3	15
116	Computer-Assisted Cyclosporine Dosing Performs Better Than Traditional Dosing in Renal Transplant Recipients: Results of a Pilot Study. Therapeutic Drug Monitoring, 2010, 32, 152-158.	1.0	15
117	No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. Nephrology Dialysis Transplantation, 2011, 26, 3767-3772.	0.4	13
118	Longâ€term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation â€“ results from an aborted trial. Clinical Transplantation, 2013, 27, E151-6.	0.8	13
119	Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. Kidney International Reports, 2020, 5, 189-198.	0.4	13
120	Shortâ€and longâ€term effects of body weight loss following calorie restriction and gastric bypass on CYP3Aâ€activity â€“ a nonâ€randomized threeâ€armed controlled trial. Clinical and Translational Science, 2022, 15, 221-233.	1.5	13
121	Diltiazem modulates cyclosporin A induced renal hemodynamic effects but not its effect on plasma endothelin-1. Clinical Transplantation, 1998, 12, 363-70.	0.8	13
122	Shortâ€and longâ€term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity. British Journal of Clinical Pharmacology, 2022, 88, 4121-4133.	1.1	13
123	A Hybrid Model Associating Population Pharmacokinetics with Machine Learning: A Case Study with Iohexol Clearance Estimation. Clinical Pharmacokinetics, 2022, 61, 1157-1165.	1.6	13
124	2â€D hydrophilic interaction liquid chromatographyâ€RP separation in urinary proteomics â€“ Minimizing variability through improved downstream workflow compatibility. Journal of Separation Science, 2010, 33, 864-872.	1.3	12
125	Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. Expert Opinion on Pharmacotherapy, 2010, 11, 1159-1166.	0.9	12
126	Endothelial Dysfunction Is Associated With Graft Loss in Renal Transplant Recipients. Transplantation, 2013, 95, 733-739.	0.5	12

#	Article	IF	Citations
127	Secreted Wnt Antagonists During Eradication of Cytomegalovirus Infection in Solid Organ Transplant Recipients. American Journal of Transplantation, 2014, 14, 210-215.	2.6	12
128	Resolution of Calciphylaxis After Urgent Kidney Transplantation in 3 Patients With End-Stage Kidney Failure. Transplantation Direct, 2016, 2, e113.	0.8	12
129	Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients. European Journal of Clinical Nutrition, 2016, 70, 824-830.	1.3	12
130	Collectin Liver 1 and Collectin Kidney 1 of the Lectin Complement Pathway Are Associated With Mortality After Kidney Transplantation. American Journal of Transplantation, 2017, 17, 265-271.	2.6	12
131	A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators. Clinical Pharmacokinetics, 2018, 57, 1459-1469.	1.6	12
132	Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. PLoS Pathogens, 2017, 13, e1006299.	2.1	12
133	Low level of MAp44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients. BMC Nephrology, 2016, 17, 148.	0.8	11
134	The EKiTE network (epidemiology in kidney transplantation - a European validated database): an initiative epidemiological and translational European collaborative research. BMC Nephrology, 2019, 20, 365.	0.8	11
135	A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. Therapeutic Drug Monitoring, 2019, 41, 11-18.	1.0	11
136	Closer to the Site of Action. Therapeutic Drug Monitoring, 2015, 37, 675-680.	1.0	10
137	Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. Transplant International, 2017, 30, 1119-1131.	0.8	10
138	Visceral fat is strongly associated with postâ€transplant diabetes mellitus and glucose metabolism 1Âyear after kidney transplantation. Clinical Transplantation, 2017, 31, e12869.	0.8	10
139	Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies. Therapeutic Drug Monitoring, 2018, 40, 292-300.	1.0	10
140	Association between insulin resistance and endothelial dysfunction in renal transplant recipients. Clinical Transplantation, 2006, 20, 195-199.	0.8	9
141	Rimonabant Affects Cyclosporine A, but Not Tacrolimus Pharmacokinetics in Renal Transplant Recipients. Transplantation, 2009, 87, 1221-1224.	0.5	9
142	Risk factors for exertional rhabdomyolysis with renal stress. BMJ Open Sport and Exercise Medicine, 2017, 3, e000241.	1.4	9
143	Fasting Status and Circadian Variation Must be Considered When Performing AUCâ€based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. Clinical and Translational Science, 2020, 13, 1327-1335.	1.5	9
144	Correlations between 4Î²-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range. European Journal of Clinical Pharmacology, 2022, 78, 1289-1299.	0.8	9

#	Article	IF	Citations
145	Plasma Levels of Marine n-3 Fatty Acids Are Inversely Correlated With Proinflammatory Markers sTNFR1 and IL-6 in Renal Transplant Recipients. , 2017, 27, 161-168.		8
146	Characterization of Cytomegalovirus Disease in Solid Organ Transplant Recipients by Markers of Inflammation in Plasma. PLoS ONE, 2013, 8, e60767.	1.1	8
147	Atorvastatin population pharmacokinetics in a realâ€life setting: Influence of genetic polymorphisms and association with clinical response. Clinical and Translational Science, 2022, 15, 667-679.	1.5	8
148	Inflammation in the early phase after kidney transplantation is associated with increased long-term all-cause mortality. American Journal of Transplantation, 2022, 22, 2016-2027.	2.6	8
149	Lowâ€target tacrolimus in de novo standard risk renal transplant recipients: A singleâ€centre experience. Nephrology, 2016, 21, 821-827.	0.7	7
150	Preserved insulin secretion and kidney function in recipients with functional pancreas grafts 1 year after transplantation: a single-center prospective observational study. European Journal of Endocrinology, 2018, 179, 251-259.	1.9	7
151	Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With Endâ€Stage Renal Disease. Clinical Pharmacology and Therapeutics, 2020, 108, 866-873.	2.3	7
152	A snapshot of European registries on chronic kidney disease patients not on kidney replacement therapy. Nephrology Dialysis Transplantation, 2021, 37, 8-13.	0.4	7
153	Deciphering transplant outcomes of expanded kidney allografts donated after controlled circulatory death in the current transplant era. A call for caution. Transplant International, 2021, 34, 2494-2506.	0.8	7
154	Accelerated 18O-labeling in urinary proteomics. Journal of Chromatography A, 2010, 1217, 8241-8248.	1.8	6
155	Increased Osteoprotegerin Predicts Poor Virological Outcome During Anticytomegalovirus Therapy in Solid Organ Transplant Recipients. Transplantation, 2015, 99, 100-105.	0.5	6
156	Complexity of Host Micro-RNA Response to Cytomegalovirus Reactivation After Organ Transplantation. American Journal of Transplantation, 2016, 16, 650-660.	2.6	6
157	Plasma n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Renal Transplant Recipients. , 2016, 26, 196-203.		6
158	Estimated glomerular filtration rate in stable older kidney transplant recipients-are present algorithms valid? A national cross-sectional cohort study. Transplant International, 2018, 31, 629-638.	0.8	6
159	Development of Kidney Transplant Fibrosis Is Inversely Associated With Plasma Marine Fatty Acid Level. , 2018, 28, 118-124.		6
160	Small effort, high impact: Focus on physical activity improves oxygen uptake (<scp>VO</scp>_{2peak}), quality of life, and mental health after pediatric renal transplantation. Pediatric Transplantation, 2018, 22, e13242.	0.5	6
161	Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. Therapeutic Drug Monitoring, 2021, 43, 247-255.	1.0	6
162	Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial. Nutrients, 2021, 13, 2361.	1.7	6

#	Article	IF	Citations
163	A Comorbidity Index and Pretransplant Physical Status Predict Survival in Older Kidney Transplant Recipients: A National Prospective Study. Transplantation Direct, 2022, 8, e1307.	0.8	6
164	Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients. European Journal of Clinical Pharmacology, 2005, 61, 59-62.	0.8	5
165	Didanosine ester prodrugs: Synthesis, albumin binding properties and pharmacokinetic studies in rats. European Journal of Medicinal Chemistry, 2009, 44, 3874-3879.	2.6	5
166	Uric acid and clinical correlates of endothelial function in kidney transplant recipients. Clinical Transplantation, 2014, 28, 1167-1176.	0.8	5
167	Bodyweightâ€adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. British Journal of Clinical Pharmacology, 2017, 83, 1350-1352.	1.1	5
168	Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score. BMC Nephrology, 2018, 19, 212.	0.8	5
169	Beyond Survival in Solid Organ Transplantation: A Summary of Expert Presentations from the Sandoz 6th Standalone Transplantation Meeting, 2018. Transplantation, 2019, 103, S1-S13.	0.5	5
170	Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients. Clinical Pharmacokinetics, 2021, 60, 1449-1462.	1.6	5
171	Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation: Opportunities and Challenges of Real-World Evidence. Transplant International, 2022, 35, 10329.	0.8	5
172	A rapid and sustained improvement of calcification propensity score (serum T₅₀) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate. Clinical Transplantation, 2017, 31, e13131.	0.8	4
173	Contraceptive Choices and Counseling in Norwegian Female Renal Transplant Recipients. Transplantation Proceedings, 2019, 51, 470-474.	0.3	4
174	Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients aged 20â€“50â€‰years: a study by the ERAâ€“EDTA Registry. Nephrology Dialysis Transplantation, 2020, 35, 534-543.	0.4	4
175	Cardiovascular Risk Factors are Inversely Associated With Omega-3 Polyunsaturated Fatty Acid Plasma Levels in Pediatric Kidney Transplant Recipients. , 2021, 31, 278-285.		4
176	Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival. Frontiers in Immunology, 2021, 12, 738927.	2.2	4
177	Timing of Kidney Clamping and Deceased Donor Kidney Transplant Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1704-1714.	2.2	4
178	Prediction of Fat-Free Mass in Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2016, 38, 439-446.	1.0	3
179	Mycophenolate Acid and Balancing the Risk for Male Allograft Recipients. Transplantation, 2017, 101, e39.	0.5	3
180	Kidney allograft subclinical rejection modulates systemic inflammation measured by Câ€reactive protein at 1Âyear after transplantation. Clinical Transplantation, 2018, 32, e13196.	0.8	3

#	Article	IF	Citations
181	Arterial stiffness is associated with visceral fat mass in kidney transplanted patientsâ€"A nationwide cohort study. Clinical Transplantation, 2018, 32, e13341.	0.8	3
182	Five decades with grandparent donors: The Norwegian strategy and experience. Pediatric Transplantation, 2020, 24, e13751.	0.5	3
183	A Simplified Iohexol-Based Method to Measure Renal Function in Sheep Models of Renal Disease. Biology, 2020, 9, 259.	1.3	3
184	Patient selection for islet or solid organ pancreas transplantation: experiences from a multidisciplinary outpatient-clinic approach. Endocrine Connections, 2021, 10, 230-239.	0.8	3
185	GENE EXPRESSION OF THE RENAL ENDOTHELIN SYSTEM IN RENAL TRANSPLANT RECIPIENTS ON CYCLOSPORINE A BASED IMMUNOSUPPRESSION. Transplantation, 1999, 67, 1056-1060.	0.5	3
186	A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients. British Journal of Clinical Pharmacology, 2021, , .	1.1	3
187	High Plasma Oxalate Levels Early After Kidney Transplantation Are Associated With Impaired Long-Term Outcomes. Transplant International, 2022, 35, 10240.	0.8	3
188	Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation. Vascular Disease Prevention, 2006, 3, 229-234.	0.2	2
189	Individualizing Transplant Therapy. , 2017, , 255-279.		2
190	Adherence to Immunosuppressive Medications in Renal Transplant Recipients â€“ Different Tools Capture Different Patients. Transplantation, 2018, 102, S282.	0.5	2
191	Trans-fatty Acids and Survival in Renal Transplantation. , 2019, 29, 169-180.		2
192	Cardiovascular rEmodelling in living kidNey donorS with reduced glomerular filtration rate: rationale and design of the CENS study. Blood Pressure, 2020, 29, 123-134.	0.7	2
193	Kidney Transplant Recipient Behavior During the Early COVID-19 Pandemic: A National Survey Study in Norway. Kidney Medicine, 2022, 4, 100389.	1.0	2
194	Quantification of mRNA levels of endothelin receptor subtypes and preproEndothelin-1 in renal needle biopsies by competitive reverse transcriptase polymerase chain reaction. Scandinavian Journal of Clinical and Laboratory Investigation, 1998, 58, 299-306.	0.6	1
195	Measuring senescence rates of patients with end-stage renal disease while accounting for population heterogeneity: an analysis of data from the ERA-EDTA Registry. Annals of Epidemiology, 2016, 26, 773-779.	0.9	1
196	Response to: â€˜Response to: Bodyweightâ€adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearanceâ€™. British Journal of Clinical Pharmacology, 2017, 83, 1357-1358.	1.1	1
197	Recovery of CYP3A Phenotype after Kidney Transplantation. Drug Metabolism and Disposition, 2017, 45, 1260-1265.	1.7	1
198	Preserved Insulin Sensitivity and Kidney Function One Year After Successful Pancreas Transplantation. Transplantation, 2018, 102, S751.	0.5	1

#	Article	IF	Citations
199	Plasma n-6 Polyunsaturated Fatty Acid Levels and Survival in Renal Transplantation. , 2018, 28, 333-339.		1
200	Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimusâ€treated transplant recipients?. British Journal of Clinical Pharmacology, 2020, 86, 2535-2535.	1.1	1
201	Changes in clinical indicators related to the transition from dialysis to kidney transplantationâ€"data from the ERA-EDTA Registry. CKJ: Clinical Kidney Journal, 2020, 13, 188-198.	1.4	1
202	Recovery of kidney function in patients treated with maintenance dialysisâ€"a report from the ERA-EDTAÂRegistry. Nephrology Dialysis Transplantation, 2021, 36, 1078-1087.	0.4	1
203	Blood Pressure Treatment in Kidney Transplant Recipientsâ€"Can We Improve?. Transplantation Direct, 2021, 7, e688.	0.8	1
204	Insulin secretion and action after pancreas transplantation. A retrospective single-center study. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 365-370.	0.6	1
205	Endothelial Dysfunction and 6-Year Risk of Mortality in Kidney Transplant Recipients. Transplantation Direct, 2022, 8, e1262.	0.8	1
206	RAPID BIOMARKER DISCOVERY IN TRANSPLANTATION BY URINARY PROTEOMICS UTILIZING ACCELERATED 18O-LABELING. Transplantation, 2010, 90, 531.	0.5	0
207	IN VIVO VIRAL MICRORNA PROFILING IN A LARGE COHORT OF TRANSPLANT PATIENTS WITH CMV DISEASE. Transplantation, 2010, 90, 27.	0.5	0
208	Response to Letter About Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease. American Journal of Transplantation, 2011, 11, 1103-1104.	2.6	0
209	SP465LONG-TERM MORTALITY IN KIDNEY TRANSPLANT PATIENTS WITH PTDM IS BETTER PREDICTED BY GLUCOSE CRITERIA THAN WITH HBA1C CRITERIA. Nephrology Dialysis Transplantation, 2015, 30, iii533-iii534.	0.4	0
210	Costimulation Blockade: America First, Canada Second â€¦ What About Norway?. American Journal of Transplantation, 2017, 17, 2230.	2.6	0
211	How to Report and Interpret Bioequivalence Data in Solid Organ Transplant Recipients. Transplantation, 2017, 101, e347.	0.5	0
212	Haptoglobin 2-2 Genotype, Patient, and Graft Survival in Renal Transplant Recipients. Progress in Transplantation, 2017, 27, 386-391.	0.4	0
213	The Authorsâ€™ Reply. Transplantation, 2018, 102, e43-e44.	0.5	0
214	SP755MARINE n-3 FATTY ACID SUPPLEMENTATION INCREASE TACROLIMUS EXPOSURE IN RENAL TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2018, 33, i603-i603.	0.4	0
215	A Simple Strategy for Diagnosis of PTDM in Stable Kidney Transplanted Patients. Transplantation, 2018, 102, S83.	0.5	0
216	A Limited Sampling Strategy to Estimate Whole Blood and Intra-lymphocyte Exposure of Everolimus in Renal Transplant Recipients using Population Pharmacokinetic Modeling and Bayesian Estimators. Transplantation, 2018, 102, S92.	0.5	0

#	Article	IF	Citations
217	High-Dose Fish Oil Supplementation Increase Tacrolimus Exposure in Stable Renal Transplant Recipients. Transplantation, 2018, 102, S599.	0.5	0
218	Outcomes of Kidney Transplantation in Former Non Kidney Solid Organ Transplant. Transplantation, 2018, 102, S85.	0.5	0
219	High Tacrolimus Clearance â€“ A Risk Factor for Development of Interstitial Fibrosis and Tubular Atrophy in the Transplanted Kidney. Transplantation, 2018, 102, S364.	0.5	0
220	SP736MARINE N-3 POLYUNSATURATED FATTY ACIDS AND BONE DENSITY IN KIDNEY TRANSPLANTATION: A DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED TRIAL. Nephrology Dialysis Transplantation, 2018, 33, i596-i596.	0.4	0
221	SP744MARINE n-3 FATTY ACID SUPPLEMENTATION REDUCES PLASMA TRIGLYCERIDES & IMPROVES FLOW MEDIATED DILATATION IN RENAL TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2018, 33, i599-i599.	0.4	0
222	SP751MARINE n-3 FATTY ACID SUPPLEMENTATION REDUCES INFLAMMATION & PREVENTS RENAL GRAFT FIBROSIS. Nephrology Dialysis Transplantation, 2018, 33, i601-i601.	0.4	0
223	A287 Effect of Gastric Bypass and Very-Low Energy Diet on cardiometabolic risk factors. Surgery for Obesity and Related Diseases, 2019, 15, S114.	1.0	0
224	233.4: The Scandinavian exchange program: Ischemic time for imported kidneys in Norway and factors associated with long ischemic time.. Transplantation, 2019, 103, S50-S50.	0.5	0
225	Reply to letter: â€œWhat about drug bioavailability in patients who had bariatric surgery and dependent on immunosuppressives?â€• Obesity Reviews, 2020, 21, e12954.	3.1	0
226	The Authorsâ€™ Reply: Placental Pathology in Pregnancies After Kidney Transplantation. Transplantation, 2020, 104, e216-e216.	0.5	0
227	P1679HYPOMAGNESAEMIA AND HYPERGLYCAEMIA AFTER KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
228	Endothelial function after pancreas transplantationâ€"A singleâ€center observational study. Clinical Transplantation, 2020, 34, e13815.	0.8	0
229	Increased systemic exposure of onceâ€daily tacrolimus in renal transplant recipients on marine omegaâ€3 fatty acid supplementation. Transplant International, 2021, 34, 1322-1324.	0.8	0
230	Posttransplant Hypertension Matters!. Transplantation, 2021, 105, e150-e150.	0.5	0
231	Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation. Vascular Disease Prevention, 2008, 3, 229-234.	0.2	0
232	Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipientâ€"No Intervention Actually Needed. Transplantation Direct, 2020, 6, e609.	0.8	0
233	Use of Statins in Kidney Transplant Recipients in Norway. International Journal of Environmental Research and Public Health, 2022, 19, 1370.	1.2	0
234	MO985: Physical Function Trajectories Predict Patient Survival in Older Recipients of Deceased Donor Kidneys. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0

#	Article	IF	Citations
235	FC 111: A Comorbidity Index and Pretransplant Physical Status Predict Survival in Older Kidney Transplant Recipients. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
236	MO952: Risk Factors of Post Transplantation Diabetes Mellitus After Kidney Transplantation. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
237	Anticoagulation and safety of renal transplant biopsy. Clinical Transplantation, 2022, 36, e14715.	0.8	0